Rigel Pharmaceuticals 배당 및 자사주 매입
배당 기준 점검 0/6
Rigel Pharmaceuticals 배당금을 지급한 기록이 없습니다.
핵심 정보
n/a
배당 수익률
-0.8%
자사주 매입 수익률
| 총 주주 수익률 | -0.8% |
| 미래 배당 수익률 | 0% |
| 배당 성장률 | n/a |
| 다음 배당 지급일 | n/a |
| 배당락일 | n/a |
| 주당 배당금 | n/a |
| 배당 성향 | n/a |
최근 배당 및 자사주 매입 업데이트
업데이트 없음
Recent updates
내러티브 업데이트 • May 13
RIGL: Execution On Breast Cancer Franchise Will Shape Future Upside Potential
Analysts trimmed their price target on Rigel Pharmaceuticals by $2 as they factor in updated views on growth, profitability and future P/E multiples, even while recent commentary suggests Pfizer's handoff of Veppanu to Rigel could support the company's long term positioning. Analyst Commentary Recent Street views on Rigel Pharmaceuticals highlight a mix of longer term opportunity around Veppanu and nearer term caution on execution, growth visibility and valuation.분석 기사 • May 12
Statutory Earnings May Not Be The Best Way To Understand Rigel Pharmaceuticals' (NASDAQ:RIGL) True Position
The latest earnings release from Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) disappointed investors. We did some...
내러티브 업데이트 • Apr 29
RIGL: Higher Future P/E And RIPK1 Rights Will Drive Bullish Repricing
Analysts have modestly adjusted their price target on Rigel Pharmaceuticals, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. However, the headline fair value estimate remains at $71.00.내러티브 업데이트 • Apr 14
RIGL: Margin And Revenue Execution Will Shape Future Upside Potential
Analysts recently lifted their price target on Rigel Pharmaceuticals by $2 to reflect updated views on the discount rate, expected revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research commentary highlights that the updated price target reflects new assumptions around discount rates, revenue potential, profit margins, and future P/E levels, but not all of this feedback is upbeat.Seeking Alpha • Apr 09
Rigel Pharmaceuticals Was Easy To Dismiss - Now It's Hard To Ignore (Rating Upgrade)
Summary Rigel Pharmaceuticals is upgraded to a speculative Buy as profitability and product momentum improve. Gavreto acquisition has materially boosted revenue and is valued at ~$245M NPV, about half RIGL's market cap. Tavalisse demand surged, carving a defensible niche in ITP; Rezlidhia seeks expansion beyond AML. Pipeline progress (R289, Eli Lilly partnership) and a strong cash position support growth, but new late-stage assets are needed by 2028. Read the full article on Seeking Alpha내러티브 업데이트 • Mar 31
RIGL: Higher Future P/E Assumptions Will Support Bullish Repricing
Analysts have raised their price target on Rigel Pharmaceuticals by $2, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish analysts describe the latest US$2 increase in the price target as a reflection of refreshed assumptions on discount rates, revenue potential, and profitability for Rigel Pharmaceuticals.내러티브 업데이트 • Mar 17
RIGL: Margin Improvement Execution Will Shape Future Upside Potential
Analysts have increased their price target on Rigel Pharmaceuticals by $2, reflecting updated views on slightly adjusted growth assumptions, a modestly higher discount rate, and expectations for improved profit margins alongside a lower future P/E. Analyst Commentary Recent research around Rigel Pharmaceuticals points to a mixed setup, where the updated price target and refined assumptions are paired with a clear emphasis on execution and margin discipline.
내러티브 업데이트 • Mar 03
RIGL: Future Returns Will Reflect Elevated 2026 Guidance And Lower Risk Profile
Analysts have lifted their price target on Rigel Pharmaceuticals by $2, citing updated assumptions around long term revenue growth, profit margins, discount rates, and a higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price target as a reflection of confidence in Rigel Pharmaceuticals' long term revenue potential and its ability to convert that into earnings over time.내러티브 업데이트 • Feb 17
RIGL: Updated Earnings Outlook And P/E Assumptions Will Drive Bullish Repricing
Analysts have lifted their fair value estimate for Rigel Pharmaceuticals by $2 to $71, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions reflected in recent Street research. Analyst Commentary Recent Street research around Rigel Pharmaceuticals has leaned positive, with bullish analysts using the higher fair value estimate and updated P/E assumptions to support their case for upside potential.내러티브 업데이트 • Feb 03
RIGL: Higher 2025 Sales Guidance And Execution Will Shape Future Upside And Risks
Analysts have lifted their fair value estimate for Rigel Pharmaceuticals from $23 to $38 per share, pointing to raised Street price targets, stronger recent product sales versus expectations, higher 2025 sales guidance in the US$225m to US$230m range, solid commercial execution, improving profitability assumptions and a higher future P/E multiple. Analyst Commentary Recent Street research has highlighted Rigel Pharmaceuticals' stronger product sales versus expectations and higher 2025 net product sales guidance in the US$225m to US$230m range, alongside raised price targets in some cases.내러티브 업데이트 • Jan 19
RIGL: Future Returns Will Reflect Raised 2025 Sales Guidance And Positive Cash Flow
Analysts have nudged their fair value estimate for Rigel Pharmaceuticals slightly higher to US$51.60 from US$51.20, citing recent price target increases and upgrades that highlight strong commercial execution, improved 2025 net product sales guidance to US$225m to US$230m, positive cash flow, and potential for further business development. Analyst Commentary Recent Street research around Rigel Pharmaceuticals has focused on how the company is executing against its guidance and what that might mean for valuation.분석 기사 • Jan 08
Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...내러티브 업데이트 • Jan 05
RIGL: Future Returns Will Reflect Stronger Execution And Raised 2025 Sales Guidance
Analysts nudged their fair value estimate for Rigel Pharmaceuticals higher from US$49.60 to US$51.20, citing stronger Q3 product sales, increased 2025 net product sales guidance to US$225m to US$230m, improved profit margin assumptions and a slightly lower future P/E multiple following recent research upgrades. Analyst Commentary Recent research updates point to a constructive shift in sentiment around Rigel Pharmaceuticals, driven by Q3 performance and revised 2025 guidance.내러티브 업데이트 • Dec 20
RIGL Q3 Execution And 2025 Guidance Will Drive Bullish Repricing
Analysts have raised their price target on Rigel Pharmaceuticals by about $2 to reflect stronger expected revenue growth, higher profit margins, and improved commercial execution highlighted by recent Street research. Analyst Commentary Bullish analysts have highlighted Rigel Pharmaceuticals as a compelling growth story in the mid-cap biotech space, pointing to recent guidance increases and stronger than expected product sales as key drivers of renewed enthusiasm.내러티브 업데이트 • Dec 06
RIGL: Future Results Will Reflect Sustained Execution Amid Emerging Commercial And Pipeline Milestones
Analysts have raised their price target for Rigel Pharmaceuticals by $3, increasing it to $49.60 from $46.60. This change reflects increased confidence in stronger revenue growth, higher profit margins and solid commercial execution highlighted in recent research.분석 기사 • Nov 27
If EPS Growth Is Important To You, Rigel Pharmaceuticals (NASDAQ:RIGL) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...내러티브 업데이트 • Nov 22
RIGL: Future Results Will Reflect Continued Strong Commercial Execution Performance
Analysts have raised their price target for Rigel Pharmaceuticals from $45.40 to $46.60. They cite stronger-than-expected product sales, improved profit margins, and continued commercial execution as key factors behind the positive outlook.분석 기사 • Nov 12
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Price Is Right But Growth Is Lacking After Shares Rocket 35%
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shareholders would be excited to see that the share price has had a great...내러티브 업데이트 • Nov 07
RIGL: Strong Commercial Execution Will Drive Momentum As Upside Is Forecast
Analysts have raised their price target for Rigel Pharmaceuticals from approximately $38.33 to $45.40. They cite improved revenue growth, expanding profit margins, and stronger commercial execution following the company’s better-than-expected sales results and increased future guidance.분석 기사 • Sep 25
Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 23% Discount?
Key Insights The projected fair value for Rigel Pharmaceuticals is US$39.23 based on 2 Stage Free Cash Flow to Equity...분석 기사 • Sep 25
Benign Growth For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Underpins Stock's 26% Plummet
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shares have retraced a considerable 26% in the last month, reversing a fair...분석 기사 • Sep 03
Does Rigel Pharmaceuticals (NASDAQ:RIGL) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...내러티브 업데이트 • Aug 07
Expansion And Clinical Pipeline Will Drive Future Opportunities Despite Risks
Despite a marked slowdown in consensus revenue growth forecasts, a significant improvement in net profit margin has driven the consensus analyst price target for Rigel Pharmaceuticals up from $33.74 to $36.83. What's in the News Raised 2025 total revenue guidance to $270–280 million (from $200–210 million), with net product sales of $210–220 million and collaboration contract revenues of $60 million (from $15–18 million).분석 기사 • Aug 06
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 28%
NasdaqGS:RIGL 1 Year Share Price vs Fair Value Explore Rigel Pharmaceuticals's Fair Values from the Community and...분석 기사 • May 15
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Compensation Looks Acceptable To Us And Here's Why
Key Insights Rigel Pharmaceuticals will host its Annual General Meeting on 22nd of May Total pay for CEO Raul Rodriguez...분석 기사 • May 09
Rigel Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) defied analyst predictions to release its first-quarter results, which were...분석 기사 • Apr 02
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26%
The Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) share price has softened a substantial 26% over the previous 30 days...Seeking Alpha • Mar 11
Rigel Looks Interesting, But Let's Wait For A Lower Price
Summary Rigel Therapeutics has expanded its oncology portfolio with REZLIDHIA and GAVRETO, alongside its original molecule TAVALISSE for chronic immune thrombocytopenia. The company’s IRAK1/4 inhibitor R289 shows promising preliminary data in lower-risk myelodysplastic syndromes, with good safety and efficacy profiles. Rigel has a strong financial position with a market cap of $366mn, $77mn cash, and projected 2025 revenue of $200-$210 million. Despite positive financials and promising drug data, since RIGL is trading at a 52-week high, I recommend waiting for a lower price to buy. Read the full article on Seeking Alpha
새로운 내러티브 • Feb 09
Advancing Pipeline And Partnerships Will Drive Future Success
Strong growth in the commercial portfolio is driven by increased demand and strategic expansions, especially with products like GAVRETO and TAVALISSE.분석 기사 • Feb 06
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Held Back By Insufficient Growth Even After Shares Climb 38%
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shares have continued their recent momentum with a 38% gain in the last...분석 기사 • Dec 20
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop
Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) shares have retraced a considerable 28% in the last month, reversing a fair...분석 기사 • Nov 08
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate
Key Insights Rigel Pharmaceuticals' estimated fair value is US$24.14 based on 2 Stage Free Cash Flow to Equity Rigel...Seeking Alpha • Oct 10
Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships
Summary Rigel Pharmaceuticals has surged 50.1% since my previous article, driven by successful execution, innovative portfolio, strategic partnerships, and pipeline progress. RIGL's FDA-approved drugs, Tavalisse, Rezlidhia, and Gavreto, are key revenue drivers. They have experienced significant sales growth and promise future contributions, particularly from Gavreto. The company’s international collaborations and ongoing clinical trials, especially for olutasidenib, indicate potential for new revenue streams and competitive IP in hematology and oncology. Despite recent price appreciation, I believe RIGL remains undervalued relative to peers. Strong revenue growth potential, efficient cost management, and good execution still justify a "Strong Buy" rating for RIGL. Read the full article on Seeking Alpha지급의 안정성과 성장
배당 데이터 가져오는 중
안정적인 배당: 과거에 RIGL 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.
배당금 증가: RIGL 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.
배당 수익률 vs 시장
| Rigel Pharmaceuticals 배당 수익률 vs 시장 |
|---|
| 구분 | 배당 수익률 |
|---|---|
| 회사 (RIGL) | n/a |
| 시장 하위 25% (US) | 1.4% |
| 시장 상위 25% (US) | 4.3% |
| 업계 평균 (Biotechs) | 2.4% |
| 분석가 예측 (RIGL) (최대 3년) | 0% |
주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 RIGL 의 배당 수익률을 평가할 수 없습니다.
고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 RIGL 의 배당 수익률을 평가할 수 없습니다.
주주 대상 이익 배당
수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 RIGL 의 지급 비율을 계산하기에는 데이터가 부족합니다.
주주 현금 배당
현금 흐름 범위: RIGL 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.
높은 배당을 제공하는 우량 기업 찾기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/20 13:09 |
| 종가 | 2026/05/20 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Rigel Pharmaceuticals, Inc.는 20명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| James Birchenough | Barclays |
| James Birchenough | BMO Capital Markets Equity Research |
| Clarence Powell | BMO Capital Markets Equity Research |